Biomea Fusion

Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate Preclinical data from ex vivo human islet experiments showed that icovamenib (BMF-219) was able to enhance the activity of glucagon-like peptide-1 (GLP-1)-based therapies, potentially leading to increased insulin secretion and improved glycemic control in patients with diabetes Phase II study (COVALENT-211), combining icovamenib with a GLP-1-based therapy, planned to begin in 2025 “Menin plays a central role in the pancreas, not only impacting the proliferation of beta cells but also the expression of GLP-1 receptors. We observed that icovamenib, when combined with either of the two most commonly used GLP-1-based therapies, tirzepatide or semaglutide, enhanced the responsiveness of human islets to the GLP-1-based therapy, leading to substantial insulin secretion under hyperglycemic conditions. The dose-dependent improvements, where glucose-stimulated insulin secretion more than doubled, are highly promising,” stated Juan Pablo Frias, MD, Biomea Fusion’s Chief Medical Officer. “Additionally, we believe the results we’ve seen with our own GLP-1 RA product candidate, BMF-650, highlight a strong potential as a next-generation, oral GLP-1 RA for both diabetes and obesity. We believe these findings open exciting new avenues for treatment.” Read More Here: https://bit.ly/4fIzDJp

The 15-15 rule is a great trick to enjoying your stash of Halloween candy while safely maintaining your blood sugar levels. Many Halloween candies contain fast-acting sugars, so they can work well for treating low blood sugar. 🍬 🍭 #HappyHalloween #DiabetesAwareness #FoodAllergyAwareness #InclusiveHalloween #SpookyAndSafe

We're #hiring a new CTM Contractor in Redwood City, California. Apply today or share this post with your network.

Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights REDWOOD CITY, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “the Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to improve the lives of patients with diabetes, obesity, and genetically defined cancers, today reported third quarter 2024 financial results and corporate highlights. “Our third quarter was a pivotal quarter for the company. Through collaborative efforts with the FDA, we efficiently resolved the clinical hold on our studies for diabetes, while keeping the expansion study readout in type 2 diabetes on track and continuing to make fundamental progress with the third development program, BMF-650. We are pleased to announce the advancement of our third clinical development candidate – a next-generation oral small molecule GLP-1 receptor agonist. Incretins have become the backbone of obesity treatment, and we believe icovamenib in combination with an incretin together can potentially become the backbone of both diabetes and obesity treatments. We have done extensive preclinical work combining icovamenib with a GLP-1 RA-based therapy and will be sharing this data together with an update on BMF-650 during our conference call on October 30th,” stated Thomas Butler, Biomea Fusion’s Chief Executive Officer and Chairman of the Board. “We are very excited for the planned remaining readouts this year, in particular the topline Week 26 data of Phase 2b COVALENT-111 with approximately 200 type 2 diabetes patients, which will help us define those patients that demonstrate response to icovamenib and will shape the Phase 3 patient population we should target.” Read More: https://bit.ly/3UsfG14

We're #hiring a new Sr. Director of Investor Relations and Corporate Development in Redwood City, California. Apply today or share this post with your network.

Don't wait for a diagnosis—be proactive! It’s recommended to have your initial blood sugar screening at age 35, with regular follow-ups every three years thereafter. At Biomea Fusion, we are committed to the power of prevention and early intervention. Let’s prioritize our health and empower our communities to stay informed about their screening needs. Together, we can build a healthier future! 💚 Learn more about our studies on diabetes on our website --> https://lnkd.in/gm-2jCRf #DiabetesAwareness #HealthScreening #PreventiveCare #BiomeaFusion #PatientCare

Why is Target Selectivity So Important in Drug Development? At Biomea Fusion, we are committed to developing therapies that are highly selective, allowing us to deliver better outcomes with fewer side effects. But why is target selectivity such a key factor? 🎯 Maximizes Effectiveness: Precise targeting ensures that a drug hits the intended biological pathway, increasing its therapeutic impact. 🎯 Reduces Side Effects: By minimizing interactions with unintended targets, selective drugs reduce the risk of harmful side effects, making them safer for patients. 🎯 Improves Patient Compliance: Fewer side effects mean better treatment adherence and, ultimately, better outcomes. 🎯 Minimizes Drug Interactions: Highly selective drugs lower the risk of unwanted drug-drug interactions, crucial for patients on multiple therapies. 🎯Enhances Understanding of Disease: Selectivity provides deeper insights into the disease mechanism, paving the way for future breakthroughs. By focusing on precision and minimizing off-target effects, we are working to create therapies that are not only effective but also safer and more tolerable for patients. Learn more about our proprietary FUSION™ System that allows us to have high target selectivity --> https://lnkd.in/giTXZQBY #Biopharma #DrugDevelopment #PrecisionMedicine #BiomeaFusion #TargetSelectivity

Halloween is a time for fun, but for some kids—especially those managing diabetes—enjoying traditional treats can be a challenge. Let’s make sure everyone can join in the spooky celebrations! 👻 Here we share some simple tricks to make your bag of treats more inclusive. 😉 Be sure to register your address on the FARE Teal Pumpkin Project page --> https://lnkd.in/gzPeQ-G5 #TealPumpkinProject #HappyHalloween #DiabetesAwareness #FoodAllergyAwareness #InclusiveHalloween #SpookyAndSafe

Halloween is a time for fun, but for some kids—especially those managing diabetes—enjoying traditional treats can be a challenge. Let’s make sure everyone can join in the spooky celebrations! 👻 Here we share some simple tricks to make your bag of treats more inclusive. 😉 Be sure to register your address on the FARE Teal Pumpkin Project page --> https://lnkd.in/gzPeQ-G5 #TealPumpkinProject #HappyHalloween #DiabetesAwareness #FoodAllergyAwareness #InclusiveHalloween #SpookyAndSafe

This Halloween, we’re excited to share the FARE Teal Pumpkin Project! 🎃 The Teal Pumpkin Project is all about making Halloween more inclusive for kids with diabetes, food allergies, and other dietary restrictions. Here is how you can participate: 1. Visit FARE website --> https://lnkd.in/gzPeQ-G5 2. Add your address to the Teal Pumpkin Project Map. 3. Show your participation with a teal pumpkin or one of FARE's free printable signs. 4. On Halloween, be sure to have non-food treats ready for trick-or-treaters! Let’s make Halloween safe and fun for all trick-or-treaters! #TealPumpkinProject #HappyHalloween #DiabetesAwareness #FoodAllergyAwareness #InclusiveHalloween #SpookyAndSafe